Leerink upgraded Amylyx (AMLX) to Outperform from Market Perform with a $10 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx doses first participant in Phase 3 LUCIDITY trial of avexitide
- Biotech Alert: Searches spiking for these stocks today
- Amylyx doses first participant in LUMINA trial
- Amylyx upgraded to Outperform from Neutral at Mizuho
- Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position